Bio tech company updates — 6/3/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Samsung is expanding its biotech investment portfolio with a new 200 billion won Life Science Fund, while simultaneously advancing AI-driven drug discovery through a partnership between Samsung Bioepis and Samsung Medical Center. These moves signal Korea's continued commitment to positioning itself as a global biotech innovation hub.
Key Findings
Samsung launches third Life Science Fund — Samsung Biologics announced the establishment of Samsung Life Science Fund 3, a 200 billion won ($145 million) venture investment vehicle backed by Samsung C&T, Samsung Biologics, and Samsung Bioepis. This brings the company's cumulative biotech operating capital to 442 billion won.
Samsung Bioepis partners on AI-driven drug discovery — Samsung Bioepis and Samsung Medical Center signed a joint research agreement to develop AI-based patient-tailored treatment technology and a drug target discovery platform through 2030. The collaboration establishes a joint consultative body and research advisory committee to strengthen next-generation biomedical research capabilities.
Details
Samsung's biotechnology expansion reflects a strategic shift toward global investment in emerging biotech ventures. The Samsung Life Science Fund 3 will invest in global biotechnology companies, managed by Samsung Venture Investment, extending Samsung's reach beyond domestic markets. This represents the company's third dedicated life science fund, demonstrating sustained commitment to the sector amid competitive global biotech development.
The Samsung Bioepis–Samsung Medical Center partnership marks a significant convergence of pharmaceutical development and clinical expertise. By combining Samsung Bioepis's biopharmaceutical capabilities with Samsung Medical Center's clinical research infrastructure, the collaboration aims to accelerate the translation of AI-powered drug discovery into clinical applications. The agreement runs through 2030, suggesting a long-term commitment to developing proprietary treatment platforms.
Sources
Samsung Bioepis, Samsung Medical Center Team Up for AI-Based Drug Target Discovery - Seoul Economic
BIO KOREA 2026 Draws 775 Firms From 59 Countries, Cementing Global Platform Status - Seoul Economic
Samsung Launches 200 Billion Won Bio Fund to Expand Next-Generation Tech Investment - Seoul Economic
koreabiomed.com
koreabiomed.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
